{"id":"NCT02993107","sponsor":"Aimmune Therapeutics, Inc.","briefTitle":"PALISADE Follow-on Study (ARC004)","officialTitle":"Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-29","primaryCompletion":"2019-05-31","completion":"2019-05-31","firstPosted":"2016-12-15","resultsPosted":"2021-12-15","lastUpdate":"2022-03-17"},"enrollment":388,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Peanut Allergy"],"interventions":[{"type":"BIOLOGICAL","name":"AR101","otherNames":[]}],"arms":[{"label":"Group 1 (Placebo Crossovers)","type":"OTHER"},{"label":"Group 2 (Active Rollovers)","type":"OTHER"}],"summary":"The purpose of this study is to demonstrate the safety, tolerability, and efficacy of AR101 through oral immunotherapy (OIT) in peanut-allergic children and adults who have completed the ARC003 study.","primaryOutcome":{"measure":"Percentage of Subjects Ages 4-17 With Treatment-related Adverse Events (TEAE)","timeFrame":"Up to 126 weeks","effectByArm":[{"arm":"Group 1 (Overall)","deltaMin":98,"sd":null},{"arm":"Group 2: Cohort 1 (QD)","deltaMin":90,"sd":null},{"arm":"Group 2: Cohort 2 (Overall)","deltaMin":36,"sd":null},{"arm":"Group 2: Cohort 3A (QD)","deltaMin":27,"sd":null},{"arm":"Group 2: Cohort 3B (Overall)","deltaMin":28,"sd":null},{"arm":"Group 2: Cohort 3C (Overall)","deltaMin":33,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":65,"countries":["United States","Canada","Germany","Ireland","Italy","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["36915184","34389504"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":100},"commonTop":["Cough","Vomiting","Abdominal pain","Urticaria","Headache"]}}